Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Monistat 1 joins Vagistat-1 in one-day yeast infection treatment market.

This article was originally published in The Tan Sheet

Executive Summary

MONISTAT 1 ENTERING ONE-DAY YEAST INFECTION TREATMENT MARKET under a licensing agreement between Johnson & Johnson and Bristol-Myers Squibb, the patent holder of the 6.5% tioconazole formulation. Bristol-Myers' Vagistat-1, which also contains 6.5% tioconazole, has been the sole entrant in the one-day vaginal yeast infection market until now. In stores nationwide starting June 15, Monistat 1 is being distributed by J&J's Personal Products Company.
Advertisement

Related Content

J&J Monistat 3 Combination Pack Cream Extension Clears FDA
J&J Monistat 3 Combination Pack Cream Extension Clears FDA
J&J Monistat 3 Combination Pack Cream Extension Clears FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS088559

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel